|
Canada
|
| |
2834
|
| |
Not Applicable
|
|
|
(Province or other Jurisdiction
of Incorporation or Organization) |
| |
(Primary Standard Industrial
Classification Code Number) |
| |
(I.R.S. Employer
Identification No.) |
|
|
Riccardo A. Leofanti, Esq.
Skadden, Arps, Slate, Meagher & Flom LLP 222 Bay Street, Suite 1750, P.O. Box 258 Toronto, Ontario, Canada M5K 1J5 (416) 777-4700 |
| |
Joseph A. Garcia
Blake, Cassels & Graydon LLP 595 Burrard Street, Suite 2600 Vancouver, British Columbia, Canada V7X 1L3 (604) 631-3300 |
|
CALCULATION OF REGISTRATION FEE
|
| |||||||||||||||
Title of Each Class of Securities to be Registered
|
| |
Amount to be
Registered(1)(2) |
| |
Proposed Maximum
Aggregate Offering Price(2)(3) |
| |
Amount of
Registration Fee(4) |
| ||||||
Common Shares
|
| | | | | | | | | | | | | | | |
Preferred Shares
|
| | | | | | | | | | | | | | | |
Debt Securities
|
| | | | | | | | | | | | | | | |
Warrants | | | | | | | | | | | | | | | | |
Units | | | | | | | | | | | | | | | | |
Subscription Receipts
|
| | | | | | | | | | | | | |||
Total | | |
US$250,000,000
|
| |
US$250,000,000
|
| |
US$31,125
|
| ||||||
|
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 8 | | | |
| | | | | 11 | | | |
| | | | | 12 | | | |
| | | | | 32 | | | |
| | | | | 32 | | | |
| | | | | 34 | | | |
| | | | | 35 | | | |
| | | | | 35 | | | |
| | | | | 36 | | | |
| | | | | 36 | | | |
| | | | | 48 | | | |
| | | | | 50 | | | |
| | | | | 50 | | | |
| | | | | 51 | | | |
| | | | | 51 | | | |
| | | | | 51 | | | |
| | | | | 54 | | | |
| | | | | 54 | | | |
| | | | | 54 | | | |
| | | | | 55 | | | |
| | | | | 55 | | |
| | |
Year Ended
December 31, |
| |
Three Months Ended
March 31, |
| ||||||||||||||||||||||||
| | |
2015
|
| |
2016
|
| |
2017
|
| |
2017
|
| |
2018
|
| |||||||||||||||
Highest rate during the period
|
| | | | 1.3990 | | | | | | 1.4589 | | | | | | 1.3743 | | | | | | 1.3513 | | | | | | 1.3088 | | |
Lowest rate during the period
|
| | | | 1.1728 | | | | | | 1.2544 | | | | | | 1.2128 | | | | | | 1.3016 | | | | | | 1.2288 | | |
Average exchange rate for the period(1)
|
| | | | 1.2907 | | | | | | 1.3231 | | | | | | 1.2986 | | | | | | 1.3238 | | | | | | 1.2647 | | |
Rate at the end of the period
|
| | | | 1.3840 | | | | | | 1.3427 | | | | | | 1.2545 | | | | | | 1.3310 | | | | | | 1.2894 | | |
Subsidiary Name
|
| |
Jurisdiction of Incorporation or Organization
|
|
Correvio LLC | | | Delaware, U.S.A. | |
Correvio International S.a.r.l | | | Switzerland | |
Exercise Date
|
| |
Number of
Shares |
| |
Exercise
Price |
| ||||||
June 23, 2017
|
| | | | 200,000 | | | | | C$ | 2.45 | | |
August 15, 2017
|
| | | | 14,444 | | | | | C$ | 1.70 | | |
August 25, 2017
|
| | | | 19,964 | | | | | C$ | 1.70 | | |
November 3, 2017
|
| | | | 3,100 | | | | | C$ | 1.65 | | |
March 26, 2018
|
| | | | 200,000 | | | | | C$ | 1.65 | | |
March 27, 2018
|
| | | | 7,943 | | | | | C$ | 1.70 | | |
March 28, 2018
|
| | | | 8,702 | | | | | C$ | 1.70 | | |
March 28, 2018
|
| | | | 3,104 | | | | | C$ | 1.65 | | |
Total
|
| | | | 457,257 | | | | | | | | |
|
Grant Date
|
| |
Number of
Options |
| |
Grant
Price |
| ||||||
August 14, 2017
|
| | | | 25,000 | | | | | C$ | 5.05 | | |
August 14, 2017
|
| | | | 42,500 | | | | | US$ | 3.92 | | |
March 23, 2018
|
| | | | 700,000 | | | | | C$ | 2.49 | | |
March 23, 2018
|
| | | | 275,000 | | | | | US$ | 1.91 | | |
June 19, 2018
|
| | | | 40,000 | | | | | C$ | 4.85 | | |
June 19, 2018
|
| | | | 65,000 | | | | | US$ | .3.68 | | |
Total
|
| | | | 1,147,500 | | | | | | | | |
|
Issuance Date
|
| |
Type of Security
|
| |
Number of
Securities |
| |
Issue
Price |
| |||
September 12, 2017
|
| |
Common shares
|
| | | | 11,783 | | | |
US$2.41(1)
|
|
September 13, 2017
|
| |
Common shares
|
| | | | 20,360 | | | |
US$2.33(1)
|
|
September 14, 2017
|
| |
Common shares
|
| | | | 10,100 | | | |
US$2.34(1)
|
|
September 15, 2017
|
| |
Common shares
|
| | | | 18,346 | | | |
US$2.33(1)
|
|
September 18, 2017
|
| |
Common shares
|
| | | | 36,170 | | | |
US$2.34(1)
|
|
September 19, 2017
|
| |
Common shares
|
| | | | 4,500 | | | |
US$2.31(1)
|
|
October 2, 2017
|
| |
Common shares
|
| | | | 50,000 | | | |
US$2.07(2)
|
|
October 3, 2017
|
| |
Common shares
|
| | | | 52,125 | | | |
US$1.95(2)
|
|
October 3, 2017
|
| |
Common shares
|
| | | | 15,200 | | | |
US$2.07(1)
|
|
October 4, 2017
|
| |
Common shares
|
| | | | 50,000 | | | |
US$2.03(2)
|
|
Issuance Date
|
| |
Type of Security
|
| |
Number of
Securities |
| |
Issue
Price |
| |||
October 5, 2017
|
| |
Common shares
|
| | | | 20,831 | | | |
US$1.92(2)
|
|
October 5, 2017
|
| |
Common shares
|
| | | | 3,400 | | | |
US$2.05(1)
|
|
October 6, 2017
|
| |
Common shares
|
| | | | 50,000 | | | |
US$2.03(2)
|
|
October 6, 2017
|
| |
Common shares
|
| | | | 1,000 | | | |
US$2.05(1)
|
|
October 9, 2017
|
| |
Common shares
|
| | | | 21,497 | | | |
US$1.92(2)
|
|
October 9, 2017
|
| |
Common shares
|
| | | | 741 | | | |
US$2.06(1)
|
|
October 10, 2017
|
| |
Common shares
|
| | | | 50,000 | | | |
US$1.99(2)
|
|
October 10, 2017
|
| |
Common shares
|
| | | | 4,400 | | | |
US$2.06(1)
|
|
October 11, 2017
|
| |
Common shares
|
| | | | 39,355 | | | |
US$2.05(1)
|
|
October 12, 2017
|
| |
Common shares
|
| | | | 50,000 | | | |
US$2.01(2)
|
|
October 12, 2017
|
| |
Common shares
|
| | | | 126,478 | | | |
US$2.06(1)
|
|
October 16, 2017
|
| |
Common shares
|
| | | | 50,000 | | | |
US$1.94(2)
|
|
October 18, 2017
|
| |
Common shares
|
| | | | 50,000 | | | |
US$1.84(2)
|
|
October 20, 2017
|
| |
Common shares
|
| | | | 50,000 | | | |
US$1.77(2)
|
|
Total
|
| | | | | | | 786,286 | | | | | |
|
Vest Date
|
| |
Number of
Shares |
| |
Exercise
Price |
| ||||||
July 4, 2017
|
| | | | 155 | | | | | | Nil | | |
August 11, 2017
|
| | | | 3,599 | | | | | | Nil | | |
August 25, 2017
|
| | | | 19,964 | | | | | | Nil | | |
September 1, 2017
|
| | | | 86 | | | | | | Nil | | |
September 14, 2017
|
| | | | 348 | | | | | | Nil | | |
November 15, 2017
|
| | | | 4,903 | | | | | | Nil | | |
December 6, 2017
|
| | | | 1,693 | | | | | | Nil | | |
December 18, 2017
|
| | | | 1,874 | | | | | | Nil | | |
January 15, 2018
|
| | | | 1,403 | | | | | | Nil | | |
February 1, 2018
|
| | | | 412 | | | | | | Nil | | |
March 28, 2018
|
| | | | 10,086 | | | | | | Nil | | |
April 3, 2018
|
| | | | 2,509 | | | | | | Nil | | |
Total
|
| | | | 47,032 | | | | | | | | |
|
Month
|
| |
High
|
| |
Low
|
| |
End
|
| |
Total Volume
|
| |||
June 2017
|
| |
C$6.00
|
| |
C$5.00
|
| |
C$5.86
|
| | | | 105,676 | | |
July 2017
|
| |
C$6.06
|
| |
C$5.16
|
| |
C$5.28
|
| | | | 52,526 | | |
August 2017
|
| |
C$5.81
|
| |
C$2.63
|
| |
C$3.04
|
| | | | 554,310 | | |
September 2017
|
| |
C$3.06
|
| |
C$2.49
|
| |
C$2.68
|
| | | | 302,964 | | |
October 2017
|
| |
C$2.67
|
| |
C$1.64
|
| |
C$2.27
|
| | | | 565,731 | | |
November 2017
|
| |
C$2.39
|
| |
C$1.68
|
| |
C$1.75
|
| | | | 470,804 | | |
December 2017
|
| |
C$2.15
|
| |
C$1.75
|
| |
C$1.91
|
| | | | 402,794 | | |
January 2018
|
| |
C$2.06
|
| |
C$1.8
|
| |
C$1.85
|
| | | | 365,592 | | |
February 2018
|
| |
C$1.89
|
| |
C$1.65
|
| |
C$1.79
|
| | | | 188,616 | | |
March 2018
|
| |
C$3.08
|
| |
C$1.78
|
| |
C$3.01
|
| | | | 878,959 | | |
April 2018
|
| |
C$3.15
|
| |
C$2.65
|
| |
C$2.98
|
| | | | 314,305 | | |
May 2018(1)
|
| |
C$3.13
|
| |
C$2.8
|
| |
C$2.95
|
| | | | 113,095 | | |
June 1 – 21, 2018
|
| |
C$5.44
|
| |
C$2.68
|
| |
C$4.94
|
| | | | 763,338 | | |
Month
|
| |
High
|
| |
Low
|
| |
End
|
| |
Total Volume
|
| ||||||||||||
June 2017
|
| | | $ | 4.60 | | | | | $ | 3.69 | | | | | $ | 4.52 | | | | | | 310,278 | | |
July 2017
|
| | | $ | 4.83 | | | | | $ | 4.15 | | | | | $ | 4.21 | | | | | | 193,275 | | |
August 2017
|
| | | $ | 4.29 | | | | | $ | 2.10 | | | | | $ | 2.44 | | | | | | 1,056,638 | | |
September 2017
|
| | | $ | 2.50 | | | | | $ | 2.00 | | | | | $ | 2.14 | | | | | | 283,913 | | |
October 2017
|
| | | $ | 2.17 | | | | | $ | 1.29 | | | | | $ | 1.76 | | | | | | 800,717 | | |
November 2017
|
| | | $ | 1.86 | | | | | $ | 1.29 | | | | | $ | 1.38 | | | | | | 407,997 | | |
December 2017
|
| | | $ | 1.72 | | | | | $ | 1.37 | | | | | $ | 1.55 | | | | | | 286,353 | | |
January 2018
|
| | | $ | 1.65 | | | | | $ | 1.46 | | | | | $ | 1.52 | | | | | | 179,024 | | |
February 2018
|
| | | $ | 1.53 | | | | | $ | 1.33 | | | | | $ | 1.43 | | | | | | 184,323 | | |
March 2018
|
| | | $ | 2.38 | | | | | $ | 1.37 | | | | | $ | 2.32 | | | | | | 1,348,393 | | |
April 2018
|
| | | $ | 2.45 | | | | | $ | 2.08 | | | | | $ | 2.35 | | | | | | 426,519 | | |
May 2018(1)
|
| | | $ | 2.45 | | | | | $ | 2.00 | | | | | $ | 2.20 | | | | | | 150,495 | | |
June 1 – 21, 2018
|
| | | $ | 4.16 | | | | | $ | 2.06 | | | | | $ | 3.70 | | | | | | 2,083,151 | | |
Capital
|
| |
Amount outstanding
as of March 31, 2018 |
| |
Amount outstanding
assuming completion of the Arrangement |
| |
Amount outstanding
as at June 21, 2018 |
| ||||||
Common Shares
|
| |
1
|
| | | | 34,868,962 | | | | | | 34,871,471 | | |
Options
|
| |
Nil
|
| | | | 3,600,057 | | | | | | 3,664,874 | | |
Warrants
|
| |
Nil
|
| | | | 1,500,000 | | | | | | 1,500,000 | | |
Long term debt
|
| |
Nil
|
| | | $ | 41,185,963 | | | | | $ | 41,185,963 | | |
Name of Person
|
| |
Name and Address of Agent
|
|
W. James O’Shea, Mark Corrigan, Robert Meyer and Justin Renz | | | Correvio Pharma Corp. 1441 Creekside Drive, 6th Floor, Vancouver, British Columbia, Canada, V6J 4S7 |
|
|
Exhibit No.
|
| |
Description
|
|
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | Consent of KPMG. | | |
| | | Powers of Attorney (included in Part III of this Registration Statement). | | |
|
7.1
|
| | Form of Indenture.* | |
|
Exhibit No.
|
| |
Description
|
|
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | Consent of KPMG. | | |
| | | Powers of Attorney (included in Part III of this Registration Statement). | | |
|
7.1
|
| | Form of Indenture.* | |
|
Signature
|
| |
Title
|
|
|
/s/ William Hunter
William Hunter
|
| | President, Chief Executive Officer and Director (Principal Executive Officer) | |
|
/s/ Justin Renz
Justin Renz
|
| | Chief Financial Officer (Principal Financial and Accounting Officer) | |
|
/s/ James O’Shea
James O’Shea
|
| | Director | |
|
/s/ Richard M. Glickman
Richard M. Glickman
|
| | Director | |
|
/s/ Mark H. Corrigan
Mark H. Corrigan
|
| | Director | |
|
/s/ Arthur H. Willms
Arthur H. Willms
|
| | Director | |
|
/s/ Robert J. Meyer
Robert J. Meyer
|
| | Director | |
Exhibit 5.1
KPMG LLP
PO Box 10426 777 Dunsmuir Street
Vancouver BC V7Y 1K3
Canada
Telephone (604) 691-3000
Fax (604) 691-3031
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Correvio Pharma Corp.
We consent to the use of our audit reports dated April 2, 2018, with respect to the consolidated balance sheets of Cardiome Pharma Corp., the predecessor of Correvio Pharma Corp. (the “Company”), as of December 31, 2017 and 2016, and the related consolidated statements of operations and comprehensive loss, stockholders’ equity and cash flows for each of the years in the three-year period ended December 31, 2017, and the related notes (the “consolidated financial statements”), and the effectiveness of internal control over financial reporting as of December 31, 2017, incorporated by reference to the Registration Statement on Form F-10, and to the reference to our firm under the heading “Auditors, Transfer Agent and Registrar” in the prospectus forming part of this Registration Statement on Form F-10.
Our report on the consolidated financial statements dated April 2, 2018 contains an explanatory paragraph that states that the Company has a history of incurring operating losses and negative cash flows from operations, which raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.
Our report on the consolidated financial statements also refers to a change in the accounting for business combinations and deferred tax assets in 2017 due to adoption of Accounting Standards Update (“ASU”) 2017-1, “Business Combinations (Topic 805): Clarifying the Definition of a Business”; and ASU 2015-17 “Balance Sheet Classification of Deferred Taxes”, respectively.
We also consent to the use of our audit report dated April 5, 2018, with respect to the combined carve-out balance sheets of the Successor to Cardiome Pharma Corp., as of December 31, 2017 and 2016 and the related combined carve-out statements of operations and comprehensive loss, net parent investment and cash flows for each of the years in the three year period ended December 31, 2017, and the related notes (the “combined carve-out financial statements”).
Our report on the combined carve-out financial statements dated April 5, 2018 contains an explanatory paragraph that states that the Successor to Cardiome Pharma Corp. has a history of incurring operating losses and negative cash flows from operations, which raise substantial doubt about its ability to continue as a going concern. The combined carve-out financial statements do not include any adjustments that might result from the outcome of that uncertainty.
KPMG LLP is a Canadian limited liability partnership and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity. KPMG Canada provides services to KPMG LLP.
The Board of Directors
Correvio Pharma Corp.
Page 2
We also consent to the use of our audit report dated April 5, 2018, with respect to the balance sheet of Correvio Pharma Corp., as of March 31, 2018 and the related statement of stockholders equity for the period from incorporation on March 7, 2018 to March 31, 2018, and the related notes.
Chartered Professional Accountants | |
June 22, 2018 | |
Vancouver, Canada |
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end
QVP@K1=BT3&L)1H_F7JK2MPU]A<&6V)''9S>M&X5V]H\JWK>84^J
MV_'FCC''O:5T!S2T]K"#AMGF#), [^RDV.!IM+-_$U6*WB7)=9M^3!/'C7O3
M046Z@B6I^9VE< Y\,]P;B\94>ZP#B=4'<[H;YUF*ZM9M$*PS?/745S(]N,AC
MLH*G@>X<:]UA>!PGRL[P[>VH ^ +/AAK-I>:_-99YJ
M^[E<>DEQ6=&-7RS*Y.,-#+J04V^V4T-7>M-9:HM'<5KDIHG=8=^ZL>Q)7A
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M##++(V.)ADD>>%K&BI)Z@ A,Q$:RN[EWX>W738,GJHED#O6&,87,.I]/%I$_59J\;@K3BU4\\N91T[BSA<;(69B_9MF::&&$['.KT.=N;Z5'DM
MI#V=HZ#U;>.WDK^+,+W.>XO<2YSC5SCM))59V$0X0>E@=.YC/7\5CB[9]Q/*
M:#A!+6]KCT =*S$3*+-GIBKXK3HM7$>&?/3-8_)Y*&UJ/7BB!D<#\[V5)&%X
MN7?Z1Y*S+NY[P_Z9P6'N,ED,[%K:[W4Z>Q68K%(T>#U/4WZB_BLT'I#EQI_3<+'1Q
M-N+^@X[R05=6FWAK7A'D6LVE'%8A+*M -=@6&R.YKF#I+#ES+O(1F5GM0QD/
M?L^Q!68KJQ,Z(M<\^=+1DB"WN)^JH#*^E;126OJ0ZT/B!P3Y.&3&W$;?K^-C
MO@">"3QO>Q/-_1.0<&&[-H\_UD=VW;]D2L326?'"8VEU;740EMY631G<]A!!
M]"U;/TD8Q["Q[0YKMA:14%!3_,KE% 8Y,OI^+@
&_-6
M$#KC3]T,IP[3:R!L4OVI+N T\JCMBF.3T>FWVEITR1X?:J&]L+VPN7VE[#);
MW,1X9(96ECVD=8-%$]VEZVC6LZP[SV5P>0CR&,G=;W,9V.:3M'41TA(F8:
M9L-
Z5/*%[S6G(MP=RWQVP"CI!L^
Z)9;5=V+1/AAQ\;,!
MFO=3.<
M$! 0$! 0$! 0$! 003GC:FYY89EC?:9[O(/M;F,GX*K3)'!Z.TVTZBOQ^4LB
M].U5'
"M=F]:/5;*Y88=^)T-B+20<,W<-DE^<\5^)6Z1I#@NOR^/-:?:E:V4WG
MZA_4&3_-)_Q16+